🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Artemis Medicare Services Limited ARTEMISMED NSE

· India
https://www.artemishospitals.com
Company Profile ↓
₹284.95
+19.20% 1Y
P/E124.43
P/B5.30
52W High₹366.60
52W Low₹205.16
Book Value₹59.05
EPS (TTM)₹2.29

Company Overview

Artemis Medicare Services Limited engages in the management and operation of multi-specialty hospitals in India and internationally. The company provides medical and surgical intervention, mix of inpatient and outpatient services. It also offers billing and insurance, childcare, emotional and support program, full body checkup, international patient, medical interpreter and record, mind body medicine, nursing, nutrition, patient and family advisory, patient advocacy and portal, pre-admission testing, and smoking cessation program services, as well as home care services. Artemis Medicare Services Limited was incorporated in 2004 and is based in Gurugram, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 26.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 10.2% CAGR over the past five years.

Healthy Margins

Operating margin of 15.2% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.28.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹1,081.00 Cr (+15.4% YoY); net profit ₹104.00 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +12.7%, earnings +46.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.2%, profit CAGR 26.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.22%
1 Year:12.70%

Compounded Profit Growth

5 Years:26.56%
1 Year:46.70%

Stock Price Performance

1 Year:+19.20%
6 Months:+22.42%
3 Months:+4.82%
1 Month:-16.40%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 49% of range
₹205.16 ₹366.60
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)30.16 · Neutral
Price Performance
1M-16.40%
3M+4.82%
6M+22.42%
1Y+19.20%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 10.2% over 5 years.
  • Profit CAGR of 26.6% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 124.4.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
124.43
Industry PE
-
Forward P/E
22.93
PEG Ratio
-
Book Value
₹59.05
Price to Book
5.30
P/S
-
EV/EBITDA
25.93
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
10.22%
Profit 5Y
26.56%
Revenue (YoY)
12.70%
Earnings (YoY)
46.70%

Profitability & Returns

ROCE
-
ROE
11.12%
ROA
7.28%
Profit Margin
10.21%
Op Margin
15.21%
Gross Margin
22.91%
EPS (Latest Qtr)
₹1.90
EPS (TTM)
₹2.29

Balance Sheet & Liquidity

Debt/Equity
0.28
Quick Ratio
-
Current Ratio
-
Debt
₹261.56 Cr
Total Assets
₹1,429.00 Cr
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
80.94%
Chg in Prom Hold
-
FII / Inst Holding
1.43%
Chg in FII Hold
-0.07%

Financial Snapshot

Enterprise Value
₹5,117.08 Cr
Total Revenue (TTM)
₹1,113.61 Cr
EBITDA
₹197.33 Cr
Free Cash Flow
₹32.00 Cr
Operating Cash Flow
₹132.00 Cr
Shares Outstanding
-
Gross Margin
22.91%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 195.00 Cr210.00 Cr225.00 Cr219.00 Cr225.00 Cr223.00 Cr241.00 Cr232.00 Cr240.00 Cr255.00 Cr275.00 Cr272.00 Cr279.00 Cr
Operating Expenses 170.00 Cr182.00 Cr191.00 Cr186.00 Cr187.00 Cr187.00 Cr199.00 Cr195.00 Cr204.00 Cr214.00 Cr224.00 Cr228.00 Cr228.00 Cr
Operating Income 17.00 Cr19.00 Cr24.00 Cr23.00 Cr27.00 Cr25.00 Cr31.00 Cr26.00 Cr24.00 Cr30.00 Cr39.00 Cr33.00 Cr39.00 Cr
EBITDA 26.00 Cr28.00 Cr34.00 Cr33.00 Cr38.00 Cr36.00 Cr42.00 Cr37.00 Cr36.00 Cr41.00 Cr51.00 Cr45.00 Cr52.00 Cr
Interest Expense 5.00 Cr7.00 Cr8.00 Cr8.00 Cr9.00 Cr8.00 Cr8.00 Cr8.00 Cr8.00 Cr7.00 Cr7.00 Cr7.00 Cr6.00 Cr
Pretax Income 14.00 Cr13.00 Cr19.00 Cr16.00 Cr20.00 Cr22.00 Cr31.00 Cr27.00 Cr29.00 Cr30.00 Cr39.00 Cr30.00 Cr40.00 Cr
Tax Provision 3.36 Cr3.38 Cr5.32 Cr4.64 Cr5.80 Cr5.28 Cr8.68 Cr6.21 Cr5.80 Cr8.70 Cr9.36 Cr7.50 Cr10.00 Cr
Net Income 11.00 Cr10.00 Cr14.00 Cr12.00 Cr14.00 Cr17.00 Cr22.00 Cr21.00 Cr23.00 Cr21.00 Cr30.00 Cr22.00 Cr30.00 Cr
Diluted EPS 0.790.721.000.851.041.221.621.501.671.532.161.411.90

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 547.00 Cr565.00 Cr408.00 Cr555.00 Cr737.00 Cr879.00 Cr937.00 Cr1,081.00 Cr
Operating Expenses 481.00 Cr503.00 Cr373.00 Cr487.00 Cr643.00 Cr746.00 Cr785.00 Cr893.00 Cr
Operating Income 46.00 Cr39.00 Cr13.00 Cr46.00 Cr63.00 Cr93.00 Cr107.00 Cr140.00 Cr
EBITDA 66.00 Cr62.00 Cr35.00 Cr68.00 Cr94.00 Cr133.00 Cr152.00 Cr188.00 Cr
Interest Expense 11.00 Cr13.00 Cr13.00 Cr12.00 Cr20.00 Cr31.00 Cr32.00 Cr28.00 Cr
Pretax Income 37.00 Cr31.00 Cr8.00 Cr37.00 Cr51.00 Cr68.00 Cr108.00 Cr139.00 Cr
Tax Provision 16.65 Cr11.16 Cr1.44 Cr5.92 Cr12.75 Cr19.04 Cr25.92 Cr34.75 Cr
Net Income 20.00 Cr19.00 Cr6.00 Cr31.00 Cr38.00 Cr49.00 Cr82.00 Cr104.00 Cr
Diluted EPS 0.971.490.492.402.883.626.006.55

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 554.00 Cr586.00 Cr600.00 Cr710.00 Cr905.00 Cr972.00 Cr1,357.00 Cr1,429.00 Cr
Total Equity 293.00 Cr313.00 Cr320.00 Cr359.00 Cr403.00 Cr449.00 Cr838.00 Cr935.00 Cr
Total Debt 114.00 Cr113.00 Cr147.00 Cr201.00 Cr286.00 Cr320.00 Cr290.00 Cr262.00 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 40.00 Cr56.00 Cr27.00 Cr60.00 Cr127.00 Cr109.00 Cr146.00 Cr132.00 Cr
Investing Cash Flow -50.00 Cr-26.00 Cr-37.00 Cr-107.00 Cr-158.00 Cr-88.00 Cr-385.00 Cr-90.00 Cr
Financing Cash Flow 14.00 Cr-27.00 Cr18.00 Cr44.00 Cr38.00 Cr-29.00 Cr267.00 Cr-50.00 Cr
Capital Expenditure -57.00 Cr-26.00 Cr-31.00 Cr-109.00 Cr-145.00 Cr-72.00 Cr-91.00 Cr-100.00 Cr
Free Cash Flow -17.00 Cr30.00 Cr-4.00 Cr-49.00 Cr-18.00 Cr37.00 Cr55.00 Cr32.00 Cr
Net Change in Cash 5.00 Cr2.00 Cr8.00 Cr-3.00 Cr7.00 Cr-8.00 Cr27.00 Cr-8.00 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------
Operating Margin % 8.4%6.9%3.2%8.3%8.5%10.6%11.4%13.0%
Net Margin % 3.7%3.4%1.5%5.6%5.2%5.6%8.8%9.6%
ROE % 6.8%6.1%1.9%8.6%9.4%10.9%9.8%11.1%
ROCE % --------

Shareholding Pattern

Insiders
80.94%
Institutions
1.43%
Public Float
7.48%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ARTEMISMED

Google News Wed, 01 Jul 2026

ARTEMISMED Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE44U21lRkRrX25lNHRuMWJxMTIzZ2N2R1FkRUE5QlNLYUd0ZnJfMzMzSjVUYm13VnhvRVhsNWhmZ1FaQllpZG1LM3pDWlN0Y0F6b3VIa2RZek9mb0dhQnJiYzFKVXVfTG1Ld3k1SWtxdlJxVlhUUnJMekIzbmVxZw?oc=5" target="_blan…

Google News Mon, 28 Sep 2026

ARTEMISMED Stays Close to Yearly Peak for Second Session - Univest

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQOWJiRnBwVV90MjNRQS1EaHNCemRMbmpIZlBJMG95eWo1VmstMVA2UEdZYTZSV0dQSU1oXzFQUktkYnFIcmZYckNvSVhWbEZtc2diZFFOVEpScGYta3poTU1WT01rYjdPXzdCQUlyNXVEMVhCQjRXRWdpWkJFUWZfSXIwVmFYbnRfR0JpdU…

Google News Mon, 06 Jul 2026

Should You Buy Artemis Medicare Services Limited (NSE:ARTEMISMED) For Its Upcoming Dividend? - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPSVlHWXlRcGtpc0RlZkRjWXIyMWtSUjNfQzFjcDA4X3VCZ3lwYWZ5cHF3WUxzVjAyM1V2N1RmM0YtOUY5eXZac1V0cVh0Y2F6NGpqUXNsVXBTN0xkblFuME5VLWhtZkZzRHpwdVJfQ1NCUXp4eTZNZW9naGdCQ0hHVWFwa0Q1X2pjZmZtSW…

Google News Mon, 08 Jun 2026

HOT STOCKS: CCL, THYROCARE Trade Above Pivot; NRBBEARING, SFL, CARTRADE Lead Gainers | TATASTEEL Slips Below 100-DMA; ITDC, CGPOWER, ARTEMISMED Among Top Losers | CCL Closes Above 50-SMA; NAM-INDIA, POWERINDIA, MED - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMiwgJBVV95cUxPeFFsTkdtb0lPWklwTVB3OFBWeDhlTnVaV3JsdXI2OGVkM1dRWkttVkpFNEdZM3NadFZ3VGVUSUNpZFVQeWdCYXl4dFpuWVp6VlNlWktjMXlYNTVBTS02cGtvR3ZLc2tLeWhhMkFFbWU3bTRCSUZsYnoxRU9NTXJUOERMYndpRmNOeF9ERX…

Google News Sat, 16 May 2026

Additional Considerations Required While Assessing Artemis Medicare Services' (NSE:ARTEMISMED) Strong Earnings - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNeDM1V3hIUkRxY1JiWjgtam94S282RGhHWWFCdkx2dFNhZ1M5QzVIXzlDb21JOFZaU1V2SHpxeEdSTWxXZ2swMTlKNFFRTWlqS05pbldsVGo3dE56V2RvcHhwVExqcDFXNkxtM1pJOUkwc0dsSVp6Ynp3SEVRZTRLT3JtYzNsanAtYnNzcX…

Google News Mon, 07 Sep 2026

ARTEMISMED 52 Week High Streak: Second Straight Session - Univest

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNbDFfRzZjcDNQVjllSDl4cHJXenlMN1dvSDduNG5CcF9qQUh6azhlaVJlNmROdlEyRlJTcjhnTWl3SGR4VnNCb0NWSlJrclZrSW12WEdZc0h0c1V3N3RWbld5RW8xaWNuMzh1MXFlSksxVFE1SDd4VVlNa0pDc3FSX0w2TXhsM2pYQmlWTj…

ARTEMISMED — Frequently Asked Questions

What is the current share price of Artemis Medicare Services Limited (ARTEMISMED)?

As of 2026-10-24 04:55 IST, Artemis Medicare Services Limited (ARTEMISMED) trades at ₹284.95 on NSE. Its 52-week range is ₹205.16 to ₹366.60.

What is the P/E ratio of ARTEMISMED?

ARTEMISMED trades at a trailing price-to-earnings (P/E) ratio of 124.43. Its price-to-book (P/B) ratio is 5.30.

What is the return on equity (ROE) of ARTEMISMED?

ARTEMISMED has a return on equity (ROE) of 11.12%.

Is ARTEMISMED a good stock to buy?

This page provides a data-driven analysis of Artemis Medicare Services Limited (ARTEMISMED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space